28514486|t|Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence
28514486|a|Limited treatment responses in schizophrenia prompted the testing of combining an antipsychotic drug treatment with a second psychotropic medication. A comprehensive evaluation of the efficacy of multiple medication combinations is missing. To summarize and compare the meta-analytically determined efficacy of pharmacologic combination strategies of antipsychotic drugs in adults with schizophrenia. Systematic search of PubMed and PsycInfo until May 13, 2016. Meta-analyses of randomized clinical trials comparing the efficacy of antipsychotic drugs combined with other antipsychotic or nonantipsychotic medications vs placebos or antipsychotic monotherapy among adults with schizophrenia. Independent reviewers extracted the data and assessed the quality of the methods of the included meta-analyses using A Measurement Tool to Assess Systematic Reviews (AMSTAR), adding 6 new items to rate their quality. Effect sizes, expressed as standardized mean difference /Hedges g or risk ratio, were compared separately for combinations with any antipsychotic drug and for combinations with clozapine. The primary outcome was total symptom reduction. Secondary outcomes included positive and negative symptoms, treatment recommendations by authors, study-defined inefficacies, cognitive and depressive symptoms, discontinuation of treatment because of any cause, and inefficacies or intolerabilities. Of 3397 publications, 29 meta-analyses testing 42 combination strategies in 381 individual trials and among 19 833 participants were included. For total symptom reductions, 32 strategies that augmented any antipsychotic drug and 5 strategies that augmented clozapine were examined. Fourteen combination treatments outperformed controls (standard mean difference /Hedges g, -1.27 [95% CI, -2.35 to -0.19] to -0.23 [95% CI, -0.44 to -0.02]; P = .05). No combination strategies with clozapine outperformed controls. The quality of the methods of the meta-analyses was generally high (mean score, 9 of a maximum score of 11) but the quality of the meta-analyzed studies was low (mean score, 2.8 of a maximum score of 8). Treatment recommendations correlated with the effect size (correlation coefficient, 0.22; 95% CI, 0.35-0.10; P < .001), yet effect sizes were inversely correlated with study quality (correlation coefficient, -0.06; 95% CI, 0.01 to -0.12; P = .02). Meta-analyses of 21 interventions fully or partially recommended their use, with recommendations being positively correlated with the effect sizes of the pooled intervention. However, the effect sizes were inversely correlated with meta-analyzed study quality, reducing confidence in these recommendations. Higher - quality trials and patient -based meta-analyses are needed to determine whether subpopulations might benefit from combination treatment, as no single strategy can be recommended for patients with schizophrenia based on the current meta-analytic literature.
28514486	0	8	Efficacy	T080	C1280519
28514486	15	28	Pharmacologic	T121	C1254351
28514486	29	40	Cotreatment	T061	C0087111
28514486	61	74	Antipsychotic	T121	C0040615
28514486	75	86	Monotherapy	T061	C0087111
28514486	90	103	Schizophrenia	T048	C0036341
28514486	129	136	Quality	T080	C0332306
28514486	154	167	Meta-analytic	T062	C0920317
28514486	168	176	Evidence	T078	C3887511
28514486	185	194	treatment	T061	C0087111
28514486	195	204	responses	T032	C0871261
28514486	208	221	schizophrenia	T048	C0036341
28514486	259	277	antipsychotic drug	T121	C0040615
28514486	278	287	treatment	T061	C0087111
28514486	302	314	psychotropic	T121	C0033978
28514486	315	325	medication	T121	C0013227
28514486	343	353	evaluation	T058	C0220825
28514486	361	369	efficacy	T080	C1280519
28514486	382	392	medication	T121	C0013227
28514486	393	405	combinations	T121	C0013162
28514486	447	464	meta-analytically	T062	C0920317
28514486	476	484	efficacy	T080	C1280519
28514486	488	501	pharmacologic	T121	C1254351
28514486	502	513	combination	T121	C0013162
28514486	528	547	antipsychotic drugs	T121	C0040615
28514486	551	557	adults	T100	C0001675
28514486	563	576	schizophrenia	T048	C0036341
28514486	599	605	PubMed	T170	C1138432
28514486	610	618	PsycInfo	T170	C1140129
28514486	639	652	Meta-analyses	T062	C0920317
28514486	656	682	randomized clinical trials	T062,T170	C0206034
28514486	697	705	efficacy	T080	C1280519
28514486	709	728	antipsychotic drugs	T121	C0040615
28514486	749	762	antipsychotic	T121	C0040615
28514486	766	794	nonantipsychotic medications	T121	C0013227
28514486	798	806	placebos	T122	C1696465
28514486	810	823	antipsychotic	T121	C0040615
28514486	824	835	monotherapy	T061	C0087111
28514486	842	848	adults	T100	C0001675
28514486	854	867	schizophrenia	T048	C0036341
28514486	881	890	reviewers	T098	C1882950
28514486	905	909	data	T078	C1511726
28514486	927	934	quality	T080	C0332306
28514486	942	949	methods	T170	C0025663
28514486	966	979	meta-analyses	T062	C0920317
28514486	988	1033	Measurement Tool to Assess Systematic Reviews	T170	C1955832
28514486	1035	1041	AMSTAR	T170	C1955832
28514486	1077	1084	quality	T080	C0332306
28514486	1086	1098	Effect sizes	T081	C0814843
28514486	1113	1141	standardized mean difference	T201	C1828170
28514486	1155	1165	risk ratio	T081	C0028873
28514486	1196	1208	combinations	T121	C0013162
28514486	1218	1236	antipsychotic drug	T121	C0040615
28514486	1245	1257	combinations	T121	C0013162
28514486	1263	1272	clozapine	T109,T121	C0009079
28514486	1304	1311	symptom	T184	C1457887
28514486	1312	1321	reduction	T080	C0392756
28514486	1351	1359	positive	T033	C1446409
28514486	1364	1372	negative	T033	C0205160
28514486	1373	1381	symptoms	T184	C1457887
28514486	1383	1408	treatment recommendations	T058	C0582427
28514486	1435	1447	inefficacies	T033	C0231184
28514486	1449	1458	cognitive	T169	C1516691
28514486	1463	1482	depressive symptoms	T184	C0086132
28514486	1484	1499	discontinuation	T058	C0457454
28514486	1503	1512	treatment	T061	C0087111
28514486	1539	1551	inefficacies	T033	C0231184
28514486	1598	1611	meta-analyses	T062	C0920317
28514486	1623	1634	combination	T121	C0013162
28514486	1653	1663	individual	T098	C0237401
28514486	1688	1700	participants	T098	C0679646
28514486	1726	1733	symptom	T184	C1457887
28514486	1734	1744	reductions	T061	C0441610
28514486	1779	1797	antipsychotic drug	T121	C0040615
28514486	1830	1839	clozapine	T109,T121	C0009079
28514486	1864	1875	combination	T121	C0013162
28514486	1876	1886	treatments	T061	C0087111
28514486	1910	1934	standard mean difference	T201	C1828170
28514486	1957	1959	CI	T081	C0009667
28514486	1991	1993	CI	T081	C0009667
28514486	2025	2036	combination	T121	C0013162
28514486	2053	2062	clozapine	T109,T121	C0009079
28514486	2090	2097	quality	T080	C0332306
28514486	2105	2112	methods	T170	C0025663
28514486	2120	2133	meta-analyses	T062	C0920317
28514486	2148	2152	high	T080	C0205250
28514486	2154	2164	mean score	T033	C3533236
28514486	2173	2186	maximum score	T081	C0449820
28514486	2202	2209	quality	T080	C0332306
28514486	2217	2238	meta-analyzed studies	T062	C0920317
28514486	2243	2246	low	T080	C0205251
28514486	2248	2258	mean score	T033	C3533236
28514486	2269	2282	maximum score	T081	C0449820
28514486	2290	2315	Treatment recommendations	T058	C0582427
28514486	2336	2347	effect size	T081	C0814843
28514486	2349	2372	correlation coefficient	T081	C0392762
28514486	2384	2386	CI	T081	C0009667
28514486	2414	2426	effect sizes	T081	C0814843
28514486	2464	2471	quality	T080	C0332306
28514486	2473	2496	correlation coefficient	T081	C0392762
28514486	2509	2511	CI	T081	C0009667
28514486	2538	2551	Meta-analyses	T062	C0920317
28514486	2619	2634	recommendations	T078	C0034866
28514486	2641	2651	positively	T033	C1446409
28514486	2672	2684	effect sizes	T081	C0814843
28514486	2726	2738	effect sizes	T081	C0814843
28514486	2770	2789	meta-analyzed study	T062	C0920317
28514486	2790	2797	quality	T080	C0332306
28514486	2799	2807	reducing	T080	C0392756
28514486	2808	2818	confidence	T041	C1704726
28514486	2828	2843	recommendations	T078	C0034866
28514486	2845	2851	Higher	T080	C0205250
28514486	2854	2861	quality	T080	C0332306
28514486	2873	2880	patient	T101	C0030705
28514486	2888	2901	meta-analyses	T062	C0920317
28514486	2934	2948	subpopulations	T098	C1257890
28514486	2968	2979	combination	T121	C0013162
28514486	2980	2989	treatment	T061	C0087111
28514486	3036	3044	patients	T101	C0030705
28514486	3050	3063	schizophrenia	T048	C0036341
28514486	3085	3098	meta-analytic	T062	C0920317
28514486	3099	3109	literature	T170	C0023866